Literature DB >> 458610

Antitumor agents. XXXIV: Mechanism of action of bruceoside A and brusatol on nucleic acid metabolism of P-388 lymphocytic leukemia cells.

I H Hall, K H Lee, S A Eigebaly, Y Imakura, Y Sumida, R Y Wu.   

Abstract

The quassinoids bruceantin, brucein D, brucein E, bruceoside A, and brusatol significantly inhibited P-388 lymphocytic leukemic cell RNA and protein synthesis in tissue culture. However, DNA synthesis inhibition seemed to correlate more directly with the anti-neoplastic activity of these compounds in the in vivo P-338 survival system. In vitro, brusatol and bruceoside A marginally inhibited 10-day P-388 lymphocytic leukemia DNA polymerase, RNA polymerase, thymidylate synthetase, dihydrofolate reductase, phosphoribosyl pyrophosphate aminotransferase, and cathepsin protease activities. In vivo studies demonstrated similar inhibition and elevated cyclic AMP levels, correlating positively with the antineoplastic activity of individual compounds. Purine synthesis was inhibited drastically by brusatol in vivo, and one key inhibition site in purine synthesis was at phosphoribosyl pyrophosphate aminotransferase, the regulatory enzyme. Histone phosphorylation and ribonucleotide reductase activity also were inhibited marginally by brusatol.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 458610     DOI: 10.1002/jps.2600680726

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  11 in total

1.  Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism.

Authors:  Dongmei Ren; Nicole F Villeneuve; Tao Jiang; Tongde Wu; Alexandria Lau; Henry A Toppin; Donna D Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-04       Impact factor: 11.205

2.  Small Molecule Inhibitor of NRF2 Selectively Intervenes Therapeutic Resistance in KEAP1-Deficient NSCLC Tumors.

Authors:  Anju Singh; Sreedhar Venkannagari; Kyu H Oh; Ya-Qin Zhang; Jason M Rohde; Li Liu; Sridhar Nimmagadda; Kuladeep Sudini; Kyle R Brimacombe; Sachin Gajghate; Jinfang Ma; Amy Wang; Xin Xu; Sampada A Shahane; Menghang Xia; Juhyung Woo; George A Mensah; Zhibin Wang; Marc Ferrer; Edward Gabrielson; Zhuyin Li; Fraydoon Rastinejad; Min Shen; Matthew B Boxer; Shyam Biswal
Journal:  ACS Chem Biol       Date:  2016-10-17       Impact factor: 5.100

3.  Brusatol Inhibits Proliferation and Metastasis of Colorectal Cancer by Targeting and Reversing the RhoA/ROCK1 Pathway.

Authors:  Rui-Jin Lu; Guo-Zhi Zhao; Rong Jiang; Shuang He; Hang Xu; Jia-Ming He; Yue Sun; Meng-Na Wu; Jian-Hua Ran; Di-Long Chen; Jing Li
Journal:  Biomed Res Int       Date:  2022-05-18       Impact factor: 3.246

4.  Anti-proliferative activity of the quassinoid NBT-272 in childhood medulloblastoma cells.

Authors:  André O von Bueren; Tarek Shalaby; Julia Rajtarova; Duncan Stearns; Charles G Eberhart; Lawrence Helson; Alexandre Arcaro; Michael A Grotzer
Journal:  BMC Cancer       Date:  2007-01-25       Impact factor: 4.430

Review 5.  Emerging roles of Nrf2 signal in non-small cell lung cancer.

Authors:  Yijun Tian; Qian Liu; Xuelian He; Xun Yuan; Yuan Chen; Qian Chu; Kongming Wu
Journal:  J Hematol Oncol       Date:  2016-02-27       Impact factor: 17.388

6.  Brusatol inhibits HIF-1 signaling pathway and suppresses glucose uptake under hypoxic conditions in HCT116 cells.

Authors:  Yapeng Lu; Bo Wang; Qian Shi; Xueting Wang; Dang Wang; Li Zhu
Journal:  Sci Rep       Date:  2016-12-16       Impact factor: 4.379

7.  Brusatol Inhibits Proliferation and Invasion of Glioblastoma by Down-Regulating the Expression of ECM1.

Authors:  Zhang'an Dai; Lin Cai; Yingyu Chen; Silu Wang; Qian Zhang; Chengde Wang; Ming Tu; Zhangzhang Zhu; Qun Li; Xianghe Lu
Journal:  Front Pharmacol       Date:  2021-12-14       Impact factor: 5.810

Review 8.  Brusatol: A potential anti-tumor quassinoid from Brucea javanica.

Authors:  Xiao-Qi Yu; Xin-Yue Shang; Xiao-Xiao Huang; Guo-Dong Yao; Shao-Jiang Song
Journal:  Chin Herb Med       Date:  2020-08-19

9.  Quassinoid analogs with enhanced efficacy for treatment of hematologic malignancies target the PI3Kγ isoform.

Authors:  Yonggang Pei; Nicky Hwang; Fengchao Lang; Lanlan Zhou; Josiah Hiu-Yuen Wong; Rajnish Kumar Singh; Hem Chandra Jha; Wafik S El-Deiry; Yanming Du; Erle S Robertson
Journal:  Commun Biol       Date:  2020-05-27

Review 10.  Design and development of Nrf2 modulators for cancer chemoprevention and therapy: a review.

Authors:  Matej Sova; Luciano Saso
Journal:  Drug Des Devel Ther       Date:  2018-09-25       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.